The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.